Log in to search using one of your social media accounts:

 

New Guidelines for HCC: The Big Questions Tackled New Guidelines for HCC: The Big Questions Tackled
Dr David Johnson provides clinicians with an overview of the new guidelines from the American Association for the Study of Liver Diseases (AASLD) on hepatocellular carcinoma.Medscape Gastroenterology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 21, 2018 Category: Consumer Health News Tags: Gastroenterology Commentary Source Type: news

Cabozantinib May Be'New Treatment Option' for Liver Cancer Cabozantinib May Be'New Treatment Option' for Liver Cancer
Cabozantinib improved overall survival and progression-free survival in pretreated patients with advanced hepatocellular carcinoma.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 24, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Promising Results for Pembrolizumab in Advanced HCC Promising Results for Pembrolizumab in Advanced HCC
Another immunotherapy has shown efficacy and safety in pretreated patients with advanced hepatocellular carcinoma.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 24, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Sorafenib Plus TACE Improves Outcomes in HCC Sorafenib Plus TACE Improves Outcomes in HCC
Adding sorafenib to transcatheter arterial chemoembolization (TACE) for patients with unresectable hepatocellular carcinoma (HCC) significantly improved several outcomes.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 22, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Independent Imaging Review Confirmed Positive Data from Primary Analysis of REFLECT Trial Evaluating Lenvatinib Compared to Sorafenib in Unresectable Hepatocellular Carcinoma
Results of tumor response assessments by blinded independent imaging review using both mRECIST and RECIST v1.1 criteria to be presented today at the Gastrointestinal Cancers Symposium WOODCLIFF LAKE, N.J., Jan. 19, 2018 -- (Healthcare Sales & Marketing ... Biopharmaceuticals, Oncology Eisai, REFLECT study, lenvatinib, Lenvima, hepatocellular carcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 19, 2018 Category: Pharmaceuticals Source Type: news

EASL and AASLD Recommendations for the Diagnosis of HCC EASL and AASLD Recommendations for the Diagnosis of HCC
This study evaluated the diagnostic performance of CT, MRI and contrast-enhanced ultrasound, alone and in combination.Liver International (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - December 15, 2017 Category: Radiology Tags: Gastroenterology Journal Article Source Type: news

Bayer receives approval in China for Stivarga ® (regorafenib) for the second-line systemic Treatment of liver cancer (for specialized target groups only)
Approval based on data from the Phase III RESORCE study where Stivarga ® (regorafenib) demonstrated significant improvement in overall survival in hepatocellular carcinoma (HCC) patients previously treated with Nexavar® (sorafenib) (Source: Bayer Company News)
Source: Bayer Company News - December 13, 2017 Category: Pharmaceuticals Source Type: news

13.12.17: Not intended for U.S. and UK Media
Bayer receives approval in China for Stivarga® (regorafenib) for the second-line systemic Treatment of liver cancerApproval based on data from the Phase III RESORCE study where Stivarga® (regorafenib) demonstrated significant improvement in overall survival in hepatocellular carcinoma (HCC) patients previously treated with Nexavar® (sorafenib)mehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - December 12, 2017 Category: Pharmaceuticals Source Type: news

HCC in Chronic HBV vs Chronic HCV After Virologic Response HCC in Chronic HBV vs Chronic HCV After Virologic Response
Does the achievement of virologic response modify the risk of hepatocellular carcinoma differently in patients with chronic hepatitis B as compared to those with chronic hepatitis C?Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 28, 2017 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Elevated Liver Cancer, Death Rates With Chronic HBV Elevated Liver Cancer, Death Rates With Chronic HBV
Patients with immune-tolerant-phase chronic hepatitis B virus (HBV) infection, who are usually not considered for treatment, face an increased risk of hepatocellular carcinoma (HCC) and death, compared with treated immune-active-phase patients, researchers from Korea report.Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - November 22, 2017 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

NAFLD Linked to Increased Cancer Incidence Rate
NAFLD strongly tied to development of hepatocellular carcinoma, CRC in males, breast cancer in females (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 20, 2017 Category: Cancer & Oncology Tags: Family Medicine, Gastroenterology, Gynecology, Internal Medicine, Nursing, Oncology, Pathology, Radiology, Journal, Source Type: news

Radiotherapy No Better Than Sorafenib for Inoperable Liver Cancer Radiotherapy No Better Than Sorafenib for Inoperable Liver Cancer
Selective internal radiotherapy (SIRT) with yttrium-90 resin microspheres does not prolong survival compared to sorafenib in patients with advanced hepatocellular carcinoma not eligible for curative treatment, according to French researchers.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - November 14, 2017 Category: Radiology Tags: Hematology-Oncology News Source Type: news

Nonalcoholic fatty liver disease increases risk of liver, colorectal, and breast cancers
(Elsevier) Nonalcoholic fatty liver disease (NAFLD) is one of the more common chronic liver diseases worldwide. It is associated with metabolic syndrome (i.e. insulin resistance and diabetes) and predisposes to cardiovascular disease. In a new study published in the Journal of Hepatology, researchers identified links not only between NAFLD and hepatocellular carcinoma (HCC), which have been well established, but also to cancers outside the liver, including colorectal and breast cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 13, 2017 Category: Cancer & Oncology Source Type: news

Direct-acting Antivirals Cut Risk of Liver Cancer Direct-acting Antivirals Cut Risk of Liver Cancer
Eradicating hepatitis C virus (HCV) with direct-acting antiviral (DAA) therapy reduces the risk of hepatocellular carcinoma by 71%, according to results of a large observational study.Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - October 25, 2017 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

‘ Liquid Biopsy ’ Shows Promise for Hepatocellular Carcinoma
DNA methylation markers show effectiveness for diagnosis and predicting prognosis (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 17, 2017 Category: Cancer & Oncology Tags: Gastroenterology, Internal Medicine, Oncology, Pathology, Journal, Source Type: news

Liquid biopsy may be new way to detect liver cancer earlier, easier
(University of California - San Diego) An international team of researchers at University of California San Diego School of Medicine and Moores Cancer Center, with colleagues at Sun Yet-sun University Cancer Center and other collaborating institutions, have developed a new diagnostic and prognosis method for early detection of hepatocellular carcinoma (HCC), based on a simple blood sample containing circulating tumor DNA. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 9, 2017 Category: International Medicine & Public Health Source Type: news

September ’s top stories: Australia’s Zero Childhood Cancer trial, Eisai & Ono ’s liver cancer trial
Australian cancer centres launched a clinical trial under the Zero Childhood Cancer programme for personalised medicine, and Eisai and Ono Pharmaceutical planned to conduct a Phase Ib combination trial for hepatocellular carcinoma (HCC). Drugdevelopm … (Source: Drug Development Technology)
Source: Drug Development Technology - October 5, 2017 Category: Pharmaceuticals Source Type: news

Outcomes After Curative Treatments of HCV-Related HCC Outcomes After Curative Treatments of HCV-Related HCC
What does the available evidence tell us about the recurrence and survival rates of HCV-related hepatocellular carcinoma after curative resection or ablation?Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 5, 2017 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Subtyping Hepatocellular Adenomas in Routine Practice Subtyping Hepatocellular Adenomas in Routine Practice
This study demonstrated that two specific subtypes of hepatocellular carcinoma can be diagnosed using only a limited immunohistochemical panel that is widely available in clinical practice.American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 4, 2017 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

Eisai reports positive Phase III trial data of Lenvima for liver cancer
Eisai has reported positive results from analysis of the subpopulation of subjects in the Greater China region participating in its Phase III REFLECT clinical trial of lenvatinib mesylate (Lenvima) to treat unresectable hepatocellular carcinoma (HCC) … (Source: Drug Development Technology)
Source: Drug Development Technology - October 2, 2017 Category: Pharmaceuticals Source Type: news

Quantitative Imaging Predicts Microvascular Invasion in Hepatocellular Carcinoma Quantitative Imaging Predicts Microvascular Invasion in Hepatocellular Carcinoma
Quantitative image analysis of preoperative CT scans can be used to predict microvascular invasion in patients with hepatocellular carcinoma (HCC), researchers report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 29, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

US FDA agrees to review Eisai ’s application for Lenvima to treat HCC
The US Food and Drug Administration (FDA) has agreed to review Eisai ’s application for an additional indication of Lenvima (lenvatinib mesylate) as a first-line treatment for patients with unresectable hepatocellular carcinoma (HCC). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 27, 2017 Category: Pharmaceuticals Source Type: news

Nivolumab Approved for Liver Cancer Nivolumab Approved for Liver Cancer
The FDA has approved the immunotherapy for use in patients with hepatocellular carcinoma who have previously been treated with sorafenib.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 25, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Bristol-Myers Squibb ’s Opdivo (nivolumab) Receives FDA Approval for the Treatment of Hepatocellular Carcinoma Patients Previously Treated with Sorafenib
PRINCETON, N.J.--(BUSINESS WIRE) September 22, 2017 --Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) injection for intravenous use for the treatment of patients... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 22, 2017 Category: Drugs & Pharmacology Source Type: news

More Than Okay to Reduce Sorafenib Dose for Liver Cancer More Than Okay to Reduce Sorafenib Dose for Liver Cancer
Initially reducing the dosage of the oral therapy did not compromise overall survival in hepatocellular carcinoma and had important benefits.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 15, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Is There a Standard for Surgical Therapy of HCC? Is There a Standard for Surgical Therapy of HCC?
This study compared different guidelines regarding indication for resection and transplantation in patients with hepatocellular carcinoma, with and without underlying cirrhosis. Is there a consensus?BMJ Open Gastroenterology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 13, 2017 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Hepatocellular carcinoma: Resection vs. transplantation
(Deutsches Aerzteblatt International) Liver transplantation is the gold standard for treating early hepatocellular cancers. Because of the lack of donors, this option is, however, available to a limited degree only. Curative liver resection is an alternative in this setting. Markus B. Schoenberg, Julian N. Bucher, and coauthors investigated whether liver resection can yield results that are comparable to those of liver transplantation. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 8, 2017 Category: Cancer & Oncology Source Type: news

For Hepatitis B Patients, Aspirin Tied to Lower Risk of HCC
5 years of aspirin therapy linked to significantly lower incidence of hepatocellular carcinoma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 1, 2017 Category: Cancer & Oncology Tags: Family Medicine, Gastroenterology, Infections, Internal Medicine, Oncology, Pathology, Pharmacy, Journal, Source Type: news

Telomere Length Prognostic in Hepatocellular Carcinoma
Shortened telomeres in tumor cells, CA - associated fibroblasts tied to reduced survival, upped recurrence (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - August 24, 2017 Category: Cancer & Oncology Tags: Gastroenterology, Oncology, Pathology, Journal, Source Type: news

Sirtex swings to a loss after ‘ challenging ’ year
Shares in Australian cancer treatment developer Sirtex Medical (ASX:SRX) plunged more than 15% yesterday after the company posted a net loss of -A$26.9 million in 2016, compared to a profit of A$54 million the year before. Sirtex has faced a barrage of obstacles this year, including a number of clinical trials that failed to meet primary endpoints. The company’s full-year results were hit by a slowdown in sales growth of its SIR-Spheres Y-90 radioactive microspheres and by the costs linked to its restructuring efforts. In June, Sirtex said it planned to cut 15% of its workforce, estimating that it would sav...
Source: Mass Device - August 23, 2017 Category: Medical Devices Authors: Sarah Faulkner Source Type: news

How Do Direct-Acting Antivirals for HCV Affect HCC Risk? How Do Direct-Acting Antivirals for HCV Affect HCC Risk?
The latest data on the controversial hepatitis C-hepatocellular carcinoma treatment link are examined.Medscape Gastroenterology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 15, 2017 Category: Consumer Health News Tags: Gastroenterology Commentary Source Type: news

Bayer ’s stivarga receives EU marketing approval for HCC treatment
The European Commission (EC) has granted marketing authorisation for Bayer ’s stivarga (regorafenib) used for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with nexavar (sorafenib). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 7, 2017 Category: Pharmaceuticals Source Type: news

Bayer Receives EU Approval for Stivarga ® (Regorafenib) for the Second-Line Systemic Treatment of Liver Cancer (for specialized target groups only)
Approval marks first treatment advance in nearly a decade and is based on data from the Phase III RESORCE study, in which Stivarga ® (regorafenib) demonstrated significant improvement in overall survival in hepatocellular carcinoma (HCC) patients previously treated with Nexavar® (sorafenib) / Nexavar is the only approved first-line treatment and Stivarga the only approved second-line therapy in Europe and the United States fo r patients with HCC (Source: Bayer Company News)
Source: Bayer Company News - August 7, 2017 Category: Pharmaceuticals Source Type: news

07.08.17: Not intended for U.S. and UK Media
Bayer Receives EU Approval for Stivarga® (Regorafenib) for the Second-Line Systemic Treatment of Liver CancerApproval marks first treatment advance in nearly a decade and is based on data from the Phase III RESORCE study, in which Stivarga® (regorafenib) demonstrated significant improvement in overall survival in hepatocellular carcinoma (HCC) patients previously treated with Nexavar® (sorafenib) / Nexavar is the only approved first-line treatment and Stivarga the only approved second-line therapy in Europe and the United States for patients with HCC mehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - August 6, 2017 Category: Pharmaceuticals Source Type: news

Eisai seeks marketing authorisation for lenvatinib from EMA
Eisai has submitted a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for first-line use of lenvatinib in patients with unresectable hepatocellular carcinoma (uHCC). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - July 27, 2017 Category: Pharmaceuticals Source Type: news

With HCV on the Run, Meet the New Challenge: HCC With HCV on the Run, Meet the New Challenge: HCC
Dr William Balistreri reviews several studies investigating the uptick in hepatocellular carcinoma.Medscape Gastroenterology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 26, 2017 Category: Consumer Health News Tags: Gastroenterology Commentary Source Type: news

Tiziana enrols first patient in Phase IIa trial of milciclib to treat HCC
UK-based biotechnology firm Tiziana Life Sciences has started patient enrolment in a Phase IIa clinical trial of milciclib for the treatment of hepatocellular carcinoma (HCC) patients. (Source: Drug Development Technology)
Source: Drug Development Technology - July 19, 2017 Category: Pharmaceuticals Source Type: news

Hepatocellular Carcinoma and DAAs: A Never Ending Story? Hepatocellular Carcinoma and DAAs: A Never Ending Story?
In this commentary, the authors examine contributing factors which might be skewing the data concerning DAAs and hepatocellular carcinoma risk in certain subsets of treated patients.Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 12, 2017 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Liver Cancer: Microwave Ablation and Ideal Surgical Margin Liver Cancer: Microwave Ablation and Ideal Surgical Margin
New findings in the treatment of hepatocellular carcinoma include results from a trial comparing microwave with radiofrequency ablation and a study of the ideal surgical margin.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 5, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Sustained Response to Direct-acting HCV Antivirals Tied to Lower HCC Risk Sustained Response to Direct-acting HCV Antivirals Tied to Lower HCC Risk
A sustained virologic response to direct-acting antiviral treatment of hepatitis C (HCV) is associated with a “ considerable ” reduction in the risk of hepatocellular carcinoma (HCC), researchers say.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 3, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Incidence of Liver Cancer After DAA Treatment of Chronic HCV Incidence of Liver Cancer After DAA Treatment of Chronic HCV
Is there a relationship between DAA therapy for chronic HCV and increased risk of hepatocellular carcinoma? Data has been conflicting.Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 27, 2017 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Bayer Receives Approval for Stivarga ® in Japan for Second-Line Treatment of Hepatocellular Carcinoma (for specialized target groups only)
Stivarga ® (regorafenib) is the first and only systemic treatment to demonstrate significant improvement in overall survival in second-line hepatocellular carcinoma (HCC) patients and the first treatment advance in nearly a decade / Pivotal trial RESORCE defines a new treatment plan in hepatocellular carcin oma (HCC) with Stivarga directly after Nexavar® (sorafenib) (Source: Bayer Company News)
Source: Bayer Company News - June 26, 2017 Category: Pharmaceuticals Source Type: news

26.06.17: Not intended for U.S. and UK Media
Bayer Receives Approval for Stivarga® in Japan for Second-Line Treatment of Hepatocellular CarcinomaStivarga® (regorafenib) is the first and only systemic treatment to demonstrate significant improvement in overall survival in second-line hepatocellular carcinoma (HCC) patients and the first treatment advance in nearly a decade / Pivotal trial RESORCE defines a new treatment plan in hepatocellular carcinoma (HCC) with Stivarga directly after Nexavar® (sorafenib)mehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - June 25, 2017 Category: Pharmaceuticals Source Type: news

Bayer Receives Positive CHMP Opinion for regorafenib for the Second-Line Systemic Treatment of Liver Cancer (for specialized target groups only)
Positive opinion based on data from the Phase III RESORCE study, in which regorafenib demonstrated significant improvement in overall survival in hepatocellular carcinoma (HCC) patients previously treated with Nexavar ® (sorafenib) / Approval could provide first treatment advance in nearly a decade / Final decision from the European Commission anticipated within the next two months (Source: Bayer Company News)
Source: Bayer Company News - June 23, 2017 Category: Pharmaceuticals Source Type: news

23.06.17: Not intended for U.S. and UK Media
Bayer Receives Positive CHMP Opinion for regorafenib for the Second-Line Systemic Treatment of Liver CancerPositive opinion based on data from the Phase III RESORCE study, in which regorafenib demonstrated significant improvement in overall survival in hepatocellular carcinoma (HCC) patients previously treated with Nexavar® (sorafenib) / Approval could provide first treatment advance in nearly a decade / Final decision from the European Commission anticipated within the next two monthsmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - June 22, 2017 Category: Pharmaceuticals Source Type: news

Lenvatinib for Unresectable Liver Cancer Noninferior to Sorafenib
Lenvatinib demonstrated noninferiority to sorafenib with regard to overall survival in patients with previously untreated, unresectable hepatocellular carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - June 19, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Gastrointestinal Cancer Liver, Gallbladder, and Biliary Tract Cancers News Source Type: news

BTG touts digital patient engagement platform with TheraSphere treatment
BTG (LON:BTG) touted data last week from a pilot study of its digital patient engagement platform IO Loop in patients with primary hepatocellular carcinoma undergoing treatment with the company’s TheraSphere transarterial radioembolization therapy. The study found that patients experienced sustained quality of life up to 3 months after treatment. The company called the study of its novel data collection tool the “the first-of-its-kind” in interventional oncology. Get the full story at our sister site, Drug Delivery Business News. The post BTG touts digital patient engagement platform with TheraSphere trea...
Source: Mass Device - June 12, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Oncology Patient Monitoring Vascular BTG Source Type: news